Loading quotes...
Forecast
The analysts' average price target is €5.61 (+623,333,233.33%). The median is €5.84 (+648,888,788.89%).
| Buy |
Â
3 |
| Hold |
Â
8 |
| Sell |
Â
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2022 | YoY |
|---|---|---|
| Revenue | 95.28m | 54.52% |
| Gross profit | 9.36m | 3,078.73% |
| Net profit | -100.25m | 7.41% |
| EBITDA | -90.76m | 3.39% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.09m |
Number of shares | 182.31m |
52-week high/low | €0.0357 - €0.022 |
| Dividends | No |
Beta | 0.70 |
P/E ratio | 0.00 |
PEG ratio | 0.00 |
P/B ratio | 0.00 |
P/S ratio | 0.00 |
Company profile
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
| Name | VIEWRAY INC. |
| CEO | Paul Ziegler Jr., |
| Headquarters | Oakwood,
oh USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 10/08/2015 |
| Employees | 295 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | VRAY |
